You are here

  • Home
  • Archive
  • Volume 81, Issue 12
  • Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’

Article info

Article menu

Download PDFPDF

Correspondence
Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’
Free

Authors

  1. Correspondence to Dr Hasan Satış, Gazi University, Ankara 06500, Turkey; hasansats{at}gmail.com
View Full Text

Citation

Satış H, Aydemir E, İzmirlioğlu K, et al
Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’
Annals of the Rheumatic Diseases 2022;81:e256.

Publication history

  • Received August 19, 2020
  • Accepted August 21, 2020
  • First published September 28, 2020.
Online issue publication 
October 18, 2023

Article Versions

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.